Boehringer Ingelheim Venture Fund
Overview
The Boehringer Ingelheim Venture Fund (BIVF) invests in groundbreaking therapeutics-focused biotechnology companies to drive innovation in biomedical research . BIVF is searching for significant enhancements in patient care through pioneering science and its clinical translation by building long-term relationships with scientists and entrepreneurs . BIVF's focus is to target unprecedented therapeutic concepts addressing high medical needs in immuno-oncology, regenerative medicine, infectious diseases and digital health .
Investments
| Company | Date | Stage | Lead |
|---|---|---|---|
| AgomAb Therapeutics | Mar 2021 | Series B | Co-investor |
| xCures | Jun 2021 | Series A | Lead |
| Bodyport | Aug 2020 | Series A | Lead |
| Centauric | Feb 2022 | Series A Extension | Co-investor |
| Dopavision | Jul 2021 | Series A | Co-investor |
For institutional investors. Book with your work email.
Sector & Stage Mix
Industry, funding stage, and valuation band breakdowns.
FAQ
Where is Boehringer Ingelheim Venture Fund based?
Boehringer Ingelheim Venture Fund is headquartered in Germany.
When was Boehringer Ingelheim Venture Fund founded?
Boehringer Ingelheim Venture Fund was founded in 2010.
How many portfolio companies does Boehringer Ingelheim Venture Fund have?
Boehringer Ingelheim Venture Fund has 45 portfolio companies in Caplight's dataset.
What are some companies in Boehringer Ingelheim Venture Fund's portfolio?
Portfolio companies visible on Caplight include AgomAb Therapeutics, xCures, Bodyport, Centauric, Dopavision.
What was Boehringer Ingelheim Venture Fund's most recent investment shown here?
Boehringer Ingelheim Venture Fund's most recent investment in this portfolio sample was in Centauric in 2022.
What sectors does Boehringer Ingelheim Venture Fund focus on?
Boehringer Ingelheim Venture Fund focuses on Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Enterprise Software, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Enterprise Software, AI, Data & Cloud Infrastructure, Enterprise Software, Enterprise Software, Frontier & Industrial Tech, Frontier & Industrial Tech, AI, Data & Cloud Infrastructure.
What company stages does Boehringer Ingelheim Venture Fund focus on?
Boehringer Ingelheim Venture Fund typically invests at the Early stage.
What is Boehringer Ingelheim Venture Fund's AUM?
Boehringer Ingelheim Venture Fund's assets under management are estimated between $250.0M and $500.0M.